Here’s what top brokers say about the ResMed (ASX:RMD) share price forecast

Could the ResMed share price keep climbing?

| More on:
A group of executives sit in front of computer screens in a darkened room while a colleague stands giving a presentation with a share price graphic lit up on the wall

Image source: Getty Images

The ResMed Inc (ASX: RMD) share price may be trading lower on Thursday morning but that hasn’t taken the shine off its impressive gains in 2021.

Since the start of the year, the sleep treatment focused medical device company’s shares have risen 31% to $36.21.

This is approximately triple the return of the S&P/ASX 200 Index (ASX: XJO) over the same period.

Where next for the ResMed share price?

The good news for investors is that a number of top brokers believe the ResMed share price can still go higher from here.

For example, the team at Credit Suisse is arguably the most bullish. It analysts currently have an outperform rating and $43.00 price target on the company’s shares.

Based on the current ResMed share price, this implies potential upside of almost 19% for investors over the next 12 months.

Elsewhere, over at Morgans, its analysts are very positive on the company and even named it one of the broker’s best ideas for November. Morgans has an add rating and $40.80 price target on its shares. This suggests potential upside of 13% for investors.

The broker commented: “While we believe the next few quarters will likely be volatile, as COVID-related demand for ventilators continues to slow and core sleep apnoea volumes gradually lift, nothing changes our medium/longer term view that the company remains well-placed as it builds a unique, patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain.”

Finally, the team at Citi currently have a neutral rating on ResMed’s shares. However, with a price target of $38.50, the broker still sees potential upside of 6.5% for investors.

All in all, the broker community appears to still see plenty of value in the ResMed share price for investors despite its strong gains this year.

Should you invest $1,000 in ResMed right now?

Before you consider ResMed, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and ResMed wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes